Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
20:38:16 EDT Mon 07 Sep 2026
Enter Symbol
or Name
USA
CA



Q:PVCT - PROVECTUS BIOPHARMACEUTICALS INC - https://www.pvct.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
PVCT - Qnot subscribed0.06+0.002253.970.80.05517  0.06  0.054480.09  0.038Sep 04Jul 2215 min RT 2¢

Recent Trades - All 0 today
Time ETExPriceChangeVolume
     
     
     
     
     
     
     
     
     
     

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2026-07-22 08:00U:PVCTNews ReleaseVisiRose Selected to Present RB-PDAT at ESCRS iNovation(TM) Day 2026 Emerging Company Showcase
2026-07-07 08:00U:PVCTNews ReleaseIndependent University of Lille Study Shows Rose Bengal Sodium Produces Opposing Mechanistic Effects at the Same Dose
2026-06-30 08:00U:PVCTNews ReleaseProvectus Biopharmaceuticals and VisiRose Announce U.S. Patent Award for Light-Independent Antibacterial Eye Drop Targeting Drug-Resistant Ocular Infections
2026-06-25 08:00U:PVCTNews ReleaseProvectus Biopharmaceuticals Launches Veripure(TM), an Open Science Program for Medical Research Access to PV-10 (rose bengal sodium)
2026-06-08 08:00U:PVCTNews ReleaseProvectus Biopharmaceuticals Announces Investor Webinar for 2026 Annual Meeting of Stockholders
2026-05-18 08:00U:PVCTNews ReleaseProvectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
2026-05-04 08:00U:PVCTNews ReleaseBascom Palmer Eye Institute Presents Four Posters on Rose Bengal Photodynamic Antimicrobial Therapy at ARVO 2026, Advancing the Clinical Case for Provectus's VisiRose Subsidiary and Rose Bengal Sodium in Infectious Keratitis
2026-04-20 18:09U:PVCTNews ReleaseProvectus Biopharmaceuticals to Hold 2026 Annual Meeting of Stockholders at Perkins Place, Its Planned New Headquarters in Knoxville, Tennessee
2026-04-02 08:00U:PVCTNews ReleaseProvectus Biopharmaceuticals Highlights Preclinical Evidence of PV-10-Mediated Immune Modulation in Burn Wound Healing; Porcine Study Demonstrates Shift Toward Pro-Regenerative Tissue Environment
2025-10-09 08:00U:PVCTNews ReleaseProvectus Biopharmaceuticals Positions PV-10 as a Differentiated Alternative to Traditional Vaccine Adjuvants; University of Calgary Research Highlights Novel STING-Pathway Activation for Improving Hepatitis B Vaccine Efficacy
2025-09-29 08:00U:PVCTNews ReleaseProvectus Biopharmaceuticals Initiates Preclinical Study of Oral PV-10 in Bladder Cancer